Search for Clinical Trial Results

Sponsored By

Mucopolysaccharidosis Type I - 127 Studies Found

Status Study
Enrolling by invitation Study Name: Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox
Condition:
Date: 2023-12-10
Recruiting Study Name: A Study of JR-141 in Patients With Mucopolysaccharidosis Type II
Condition: Mucopolysaccharidosis II
Date: 2017-04-10
Interventions: Drug: JR-141 IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week
Recruiting Study Name: Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
Condition:
Date: 2023-12-10
Completed Study Name: To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients
Condition: Mucopolysaccharidosis II
Date: 2011-02-22
Interventions:
  • Drug: GC1111_0.5mg/kg
  • Drug: GC1111_1.0mg/k
Recruiting Study Name: The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients
Condition: Hunter Syndrome
Date: 2014-01-19
Recruiting Study Name: Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age
Condition: Hunter Syndrome
Date: 2015-05-20
Interventions: Drug: Elaprase for intravenous (IV) infusion Patients enrolled in this study will receive once-weekly IV
Completed Study Name: Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome
Condition: Hunter Syndrome
Date: 2011-10-06
Interventions: Other: No treatment
Completed Study Name: An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients
Condition: Hunter Syndrome
Date: 2009-04-16
Interventions: Biological: Idursulfase Patients received idursulfase as prescribed by their physician following locally
Completed Study Name: Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)
Condition: Mucopolysaccharidosis II
Date: 2003-09-29
Interventions:
  • Biological: Iduronate-2-sulfatase enzyme replacement therapy

Completed Study Name: A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
Condition: Hunter Syndrome
Date: 2009-06-12
Interventions:
  • Other: Control 3 dose cohorts

Next >>>